Join to View Full Profile
4460 Bissonnet StSte 200Bellaire, TX 77401
Phone+1 713-524-3434
Fax+1 713-524-3220
Dr. Wykoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Board Certified by the American Board of Ophthalmology. Partner at Retina Consultants of Houston & Clinical Assistant professor at Weill Cornell Medical College, Houston Methodist Hospital. Research interests: angiogenesis & exudative retinal diseases as well as vitreoretinal surgery topics including trauma, retinal detachments, diabetic retinopthay, & macular holes. Principle investigator on numerous clinical trials including novel approaches to treating AMD, RVO and diabetic retinopathy. Member of the Macula Society, ASRS, AAO, and ARVO.
Education & Training
B Palmer Eye Institute - A B Leach EyeChief Residency, Chief Resident & Co-Director of Ocular Trauma, 2010 - 2011
University of Miami Hospital and ClinicsFellowship, Surgical Retina and Vitreous, 2009 - 2011
University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2006 - 2009
Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 2005 - 2006
Harvard Medical SchoolClass of 2005
Certifications & Licensure
TX State Medical License 2011 - 2026
FL State Medical License 2009 - 2015
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Start of enrollment: 2012 Oct 01
- Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab Start of enrollment: 2012 Dec 01
- A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- 1 citationsNew targets in diabetic retinopathy: addressing limitations of current treatments through the Sema3A/Nrp1 pathway.Sobha Sivaprasad, Chui Ming Gemmy Cheung, Martin Gliem, Charles C Wykoff, Nina Zippel
Eye. 2025-12-01 - Geographic Atrophy Progression in Clinical Practice Before and After Pegcetacoplan Treatment.Jessica A Cao, Avery W Zhou, Gail M Teagle, Liisa M Baumann, Ryan A Sahraravand
Vision. 2025-11-18 - Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial.Diana V Do, Charles C Wykoff, Sobha Sivaprasad, David M Brown, David S Boyer
Ophthalmology. 2025-11-10
Journal Articles
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyCharles C Wykoff, Srinivas R Sadda, JAMA Ophthalmology
- Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging with Ultrawide-Field Imaging for Determining Severity of Diabetic RetinopathyLee M Jampol, Lloyd Paul Aiello, Jennifer K Sun, Szilard Kiss, Charles C Wykoff, JAMA
Authored Content
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
Press Mentions
Opus Genetics Doses First Participant in OPGx-BEST1 Gene Therapy Trial for Best DiseaseNovember 13th, 2025- Trial Participants’ Vision Worsened 3 Years After Diabetic Retinopathy Treatment StudyOctober 22nd, 2025
- First FDA-Approved Treatment for MacTel Performed; Dr. Wykoff Shares ExperienceAugust 8th, 2025
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
